Training activity information
Details
Perform tests to detect or monitor donor specific antibodies for post-transplant patients
Type
Entrustable training activity (ETA)
Evidence requirements
Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion.
Reflection at multiple timepoints on the trainee learning journey for this activity.
Considerations
- Local procedures and national guidelines
- Local protocols for the clinical and laboratory monitoring of patients who have received solid organ transplantation
- Post-transplant complications
- Patient centred care and support, including urgency of testing and implication of results
- Infection control
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
What does success look like?
- Identify what is expected of you in relation to successfully performing assays to detect or monitor donor specific antibodies (DSA) in patients post-transplantation.
- Consider how the learning outcomes apply, specifically in relation to performing the relevant laboratory investigations and practicing in accordance with quality standards.
- Discuss with your training officer to gain clarity of what is expected of you in relation to appropriate assay selection (e.g., single antigen beads), precise technique for longitudinal monitoring, and required quality control checks.
What is your prior experience of this activity?
- Think about what you already know about antibody detection methods and the clinical context of graft rejection and immunosuppression.
- Consider possible challenges you might face during the activity, such as low sample volume from frequently monitored patients, technical issues with the analyser, or difficulty in comparing results against complex historical baseline data.
- Recognise the scope of your own practice for this activity i.e. know when you will need to seek advice or help, and from whom. You will need to seek advice from your Training Officer when required, for example if the DSA assay yields highly unexpected results (e.g., massive increase) that conflict with the patient’s stable clinical condition, requiring urgent verification.
- Acknowledge how you feel about performing assays that monitor the ongoing immunological status of a functioning graft.
What do you anticipate you will learn from the experience?
- Consider the specific skills you want to develop, such as methodical documentation of MFI trends over time or proficiency in specialised single antigen bead assays.
- Identify the specific insights you hope to gain into the clinical significance of DSA titre changes in relation to potential graft rejection mechanisms.
What additional considerations do you need to make?
- Consult actions identified following previous experiences of antibody testing or longitudinal patient monitoring.
- Identify important information you need to consider before embarking on the activity, such as reviewing the patient’s DSA baseline status, the specific monitoring frequency protocol, and the donor’s HLA typing results.
In action
Is anything unexpected occurring?
- Are you noticing anything surprising or different from what you anticipate whilst performing tests to detect or monitor donor specific antibodies (DSA) for post-transplant patients?
- Are you encountering situations such as:
- The DSA assay results showing unexpected patterns e.g., sudden significant increase/decrease not matching the clinical picture, or new specificities?
- Technical issues arising with patient sample quality e.g., haemolysis impacting MFI values or difficulty accessing/comparing historical DSA data?
How are you reacting to the unexpected development?
- How is this impacting your actions? For example, are you responding to the situation appropriately? Are you adapting or changing your approach to data review or assay execution?
- Consider the steps you are taking in the moment, such as:
- Immediately troubleshooting technical issues (e.g., re-centrifuging samples, re-reading beads) to verify the result accuracy
- Consulting the patient’s clinical notes to seek context for an unexpected change in DSA titre
- How are you feeling in that moment? For instance, are you finding it difficult to reconcile the current result with the historical data? Is it affecting your confidence in performing the testing independently?
What is the conclusion or outcome?
- Identify how you are working within your scope of practice. For example, are you successfully verifying the result accuracy after checking technical parameters? Or are you needing support because a highly significant, unexpected increase in DSA requires immediate pathological review and clinical escalation?
- What are you learning as a result of the unexpected development? For example, are you mastering the subtle art of real-time DSA troubleshooting? Or gaining insight into the importance of coordinating laboratory findings with clinical status in post-transplant monitoring?
On action
What happened?
- Begin by summarising the key steps you took when performing Donor Specific Antibody (DSA) monitoring tests.
- Consider specific events, actions, or interactions which felt important, such as how you ensured consistency between longitudinal monitoring runs or performed the single antigen bead assay.
- Include any ‘reflect-in-action’ moments where you had to adapt to the situation as it unfolded, for instance, immediately re-reading the sample when MFI values showed an unexplained sudden spike or adjusting the wash steps to ensure consistency with the established baseline protocol.
- How did you feel during this experience, e.g., did you feel meticulous about longitudinal consistency or concerned about potential technical drift?
How has this experience contributed to your developing practice?
- Identify what learning you can take from this experience regarding performing DSA testing/monitoring methods. What strengths did you demonstrate, e.g., vigilant adherence to longitudinal testing protocols?
- What skills and/or knowledge gaps were evident, e.g., understanding the impact of certain immunosuppressants on DSA detection or managing MFI variability?
- Compare this experience against previous engagement with similar activities – were any previously identified actions for development achieved? Has your practice improved in performing the relevant laboratory investigations?
- Identify any challenges you experienced, such as MFI variability, consistency checks, or needing advice on scope of practice regarding interpreting initial monitoring results without senior input, and how you reacted to this.
What will you take from the experience moving forward?
- Identify the actions or ‘next steps’ you will now take to support the assimilation of what you have learnt, including from any feedback you have received, with regards to improving your proficiency with DSA testing/monitoring methods and clinical context.
- What will you do differently next time you approach performing these tests, for instance, by proactively comparing control performance against the historical mean?
- Do you need to practise any aspect of the activity further, such as single antigen bead assay interpretation or key learning outcomes related to practicing in accordance with quality standards?
Beyond action
Have you revisited the experiences?
- How have your subsequent experiences of performing tests to monitor donor specific antibodies (DSA) since completing this specific training activity led you to revisit your initial approach or decisions during that activity? For example, how a subsequent post-transplant sample suffered from interference or technical issues unique to the post-transplant state forced you to re-evaluate the diligence of your initial assay technique for challenging samples during your first attempt at this training activity.
- Considering what you understand about antibody kinetics, sample interference post-transplant, and the clinical context of DSA monitoring now, were the actions or considerations you identified after your initial reflection on this training activity sufficient?
- How have you since implemented or adapted improvements in your assay technique for post-transplant samples or ensuring correct identification of donor-specific antibodies based on further learning and experiences? For example, how you proactively reviewed and integrated the patient’s immunosuppression regimen into your technical documentation prior to testing.
- Has discussing the challenges of testing post-transplant samples or the importance of monitoring trends with colleagues, peers, or supervisors changed how you now view your initial experience in this training activity? For example, how professional storytelling with a senior colleague about a time when a failure to track DSA trends led to ambiguity in rejection management refined your understanding of the critical nature of longitudinal data analysis during post-transplant monitoring.
How have these experiences impacted upon current practice?
- How has the learning from this initial training activity, in combination with subsequent experiences of DSA monitoring, contributed to your overall confidence and competence in executing assays for monitoring transplant recipients, particularly in preparing for observed assessments (DOPS or OCEs) such as ‘Perform tests to monitor post-transplant donor specific antibodies’? For example, how your accumulated ability in performing specialised laboratory techniques and managing longitudinal data now enables you to manage complex monitoring assays confidently during a DOPS assessment.
- How has reflecting back on this specific training activity, combined with everything you’ve learned since, shaped your current approach to post-transplant antibody testing?
- How does this evolved understanding help you identify when antibody results in a post-transplant patient are unexpected or require expert immunological and clinical interpretation and when this is beyond your scope of practice? For example, how your evolved approach means you now routinely seek expert immunological interpretation immediately when a significant, unexplained rise in DSA is detected, recognising this requires senior pathological input regarding potential rejection.
- Looking holistically at your training journey, how has this initial DSA monitoring experience, revisited with your current perspective, contributed to your development in meeting the learning outcomes related to interpreting test results and preparing clinical reports? For example, how this foundational experience has supported your development in transferable skills such as understanding longitudinal data and working with challenging samples that will be valuable in future roles or responsibilities.
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 5 |
Outcome
Prepare clinical reports for laboratory investigations for a range of patients referred to an H&I laboratory. |